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Background: The current retrospective study aims to identify some determinants of survival
in  metastatic breast cancer.
Methods: The study concerned 332 patients with synchronous (SM) or metachronous (MM)
metastatic breast cancer treated between January 2000 and December 2007. Statistical com-
parison between subgroups of patients concerning survival was carried out employing
log-rank test for the invariable analysis and Cox model for the multivariable analysis. Factors
included: age group (≤50 years vs. >50; ≤70 years vs. >70; ≤35 years vs. >35), menopausal sta-
tus, presentation of metastatic disease (SM vs. MM), disease free interval (DFI) (≤24 months
vs.  >24 months; ≤60 months vs. >60 months), performance status at diagnosis of metastatic
disease (PS) (0–1 vs. >1), hormone receptors (HR), number of metastatic sites (1 site vs. >1),
nature of the metastatic site (visceral vs. non visceral), ﬁrst line therapy, surgery of the
primary tumor (SPT), locoregional radiotherapy (LRRT) and use or not of bisphosphonates.
Results: Overall survival at 5 years was 12%. Positive prognostic factors in univariate anal-
ysis were: age ≤ 70 years, hormono-dependence of the tumor, good PS (PS 0–1), less than
two  metastatic sites, no visceral metastases, DFI ≥ 24 months, SPT or LRRT. In multivariate
analysis, favorable independent prognostic factors included: good PS (PS 0–1), absence of
visceral metastases (liver, lung, brain) and age ≤ 70 years.
Conclusion: Many of the prognostic factors in metastatic breast cancer found in our studyare  known in the literature but some of them, like the application of locoregional treatment
(radiotherapy or surgery) and the use of bisphosphonates, need to be further investigated
in  randomized clinical trials.
© 2013 Greater Poland Cancer Centre. Published by Elsevier Urban & Partner Sp. z o.o. All
6–10% of affected patients present metastatic breast can-.  Backgroundreast cancer is the most common malignant disease
mong women in the world.1 Despite the advances in
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the diagnosis and in the treatment of breast cancer,om (R. Bouzguenda).
cer at diagnosis and 30–40% will develop metastasis during
the evolution of their disease.2,3 The peak of relapses is
seen between 2 and 3 years.2 The onset of metastases,
ed by Elsevier Urban & Partner Sp. z o.o. All rights reserved.
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Table 1 – Distribution of metastatic location.
Metastatic locations Numbers (%)
Bone
Bone and others 225 (67.6)
Only bone 85 (38)
Liver
Liver and others 116 (35)
Only liver 31 (27)
Lung
Lung and others 103 (31)
Only lung 28 (27)
Node 56 (16.8)
Brain
Brain and others 37 (11.1)
Only brain 6 (16)
The ﬁrst line CT was anthracycline-based in 137 casesSkin 25 (7.5)
Ovarian 5 (1.5)
as a sign of incurability, constitutes a major problem of
care.4
The emergence of new drugs and recent therapeutic strate-
gies have not only helped to extend the median survival time
(around 30 months now) but also to improve the quality of
patients’ lives.5
The aim of this retrospective study is to identify the progno-
stic factors inﬂuencing the survival of patients affected with
metastatic breast cancer taken over in the south of Tunisia.
2.  Materials  and  methods
This study included 332 patients with histologically proven
breast cancer with synchronous (SM) or metachronous (MM)
metastasis (MTS). The study was conducted over eight years
(from January 2000 to December 2007). Data were updated on
January 2010. We  collected, for each patient, the epidemio-
logical and clinical data, the therapeutic modalities and the
evolution. The treatment of the primary tumor consisted,
according to the operability and the response to chemother-
apy (CT), in the surgery (mastectomy or tumorectomy with or
without axillary lymph nodes dissection) and/or radiotherapy
(RT) at a dose of 36 Gy in 12 sessions. The metastasectomy
and/or the RT had been indicated for solitary metastasis. The
RT had been, also, used for painful bone metastasis, in case
of spinal cord compression, for consolidation of threaten-
ing bone lesions and/or in case of cerebral metastasis with a
dose of 30 Gy in 10 sessions. The ﬁrst line systemic treatment
for metastatic relapse consisting in hormone therapy (HT) or
chemotherapy (CT) depends on the disease free interval (DFI)
between the end of the adjuvant treatment and the metastatic
relapse, of the positivity of hormonal receptors (HR), charac-
teristics of metastasis and the patient PS based on the WHO
classiﬁcation. Bisphosphonates (Pamidronate, Zoledronate or
Ibandronate) were prescribed in cases of bone metastases.
The OS was deﬁned as the time between the date of diagno-
sis and the date of death or last visit for the group of patients
presenting SM and as the time between the date of relapse
and the date of death or last visit for patients with MM using
the Kaplan–Meier. The OS was analyzed in relation to different
prognostic factors: the age (≤50 years vs. >50; ≤70 years vs. >70;
≤35 years vs. >35), the menopausal status (premenopausaliotherapy 1 8 ( 2 0 1 3 ) 127–132
vs. postmenopausal); the presentation of metastatic disease
(SM vs. MM), the disease free interval (DFI) (≤24 months vs.
>24, ≤60 months vs. >60), the performance status (PS) (0–1
vs. >1), the estrogen receptor (ER) (ER+ vs. ER−);  the hormone
receptors for progesterone (PR) (PR+ vs. PR); the number of
metastatic sites (1 site vs. >1 site); the nature of the metastatic
site (visceral vs. non visceral), the type of the ﬁrst line medi-
cal treatment (CT vs. HT), the surgery of the primitive tumor
(SPT) vs. no SPT, the loco regional RT (LRRT) vs. no LRRT and
the use of biphosphonates (biphosphonates vs. no biphospho-
nates). The study of survival based on prognostic factors was
performed using the log-rank test for univariate analysis and
Cox model for multivariate analysis.
3.  Results
3.1.  Characteristics  of  patients  and  of  the  disease
There were 129 cases of SM (39%) and 203 cases of MM (61%).
The median age was 50.5 years (range: 25–85 years). The PS
was 0–1 in 72% of cases. Fifty-ﬁve percent of our patients
were premenopaused at diagnosis. The anatomopathological
examination concluded to an invasive ductal carcinoma in
82% of the cases, a II or III histological grade in 98% of cases and
a positive HRs in 56% of the cases. Her2 status was determined
by immunohistochemistry for 3 patients, this marker was over
expressed in one of them. The rate of CA15-3 was increased in
72% of the speciﬁed cases. The median time of relapse in MM
cases was 31 months (2–248 months). The distribution of the
metastatic locations is detailed in Table 1. One hundred and
ﬁfty-seven patients (47.3%) had a single metastatic site.
3.2.  Treatment
3.2.1.  Surgery
Two hundred and ninety-eight patients were treated. Fifty-two
patients were treated by surgery for their primitive tumor:
39 underwent a mastectomy with axillary node dissection,
eleven had a mastectomy without axillary node dissection and
two had a lumpectomy with axillary node dissection. Twelve
patients had surgeries of secondary localizations: Hepatic
metastasectomy (two patients), cerebral metastasectomy (two
patients), bilateral annexectomy (one patient), spinal lymph
node dissection (one patient) and bone consolidating surgery
(six patients).
3.2.2.  Medical  treatment
Amongst the 298 treated patients, 283 patients (94.6%)
received a ﬁrst line medical treatment consisting in CT (258
patients) or HT (25 patients). The untreated patients were lost
to follow up at diagnosis of metastases or had a poor PS pre-
venting treatment. Among the 265 patients who  received CT
(in ﬁrst line or after ﬁrst line HT), 119 (44.9%) were treated with
second line CT and 47 (17.7%) with 3 lines of CT or more.(51.6%), taxane-based in 88 cases (33.2%), vinorelbine-based
in 48 cases (18.2%) and platinum-based in 19 cases (7.3%). Fif-
teen patients had a combination of anthracycline with taxane
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Table 2 – Prognostic factors in univariate analysis.
Prognostic factors 3 years OS 5 years OS p
Age (years)
<35 vs. >35 25% vs. 31% 15% vs. 12% 0.2
<50 vs. >50 34% vs. 27% 12.4% vs. 11.7% 0.3
<70 vs. >70 32.2% vs. 15.4% 12.8% vs. 3.8% 0.006
Menopausal status
Postmenopausal vs. premenopausal 25.4% vs. 35% 11.3% vs. 13% 0.25
DFI (Months)
<24 vs. >24 21.7% vs. 37% 6.8% vs. 14.9% 0.004
<60 vs. >60 26% vs. 58% 8.7% vs. 25.8% 0.008
PS
(0–1) vs. ≥1 39.3% vs. 9.3% 15.2% vs. 4.6% <0.00001
HR
ER (+) vs. ER (−) 41.5% vs. 21.4% 19% vs. 5% <0.00001
PR (+) vs. PR (−) 42.4% vs. 22.3% 18% vs. 6.5% <0.00001
MTS
SM vs. MM 34% vs. 29% 16.4% vs. 10.3% 0.25
Visceral vs. non visceral 26% vs. 43.5% 8% vs. 25% <0.00001
1 site vs. >1 site 41% vs. 21% 15% vs. 9% <0.001
Medical treatment
CT vs. HT 21% vs. 52% 4% vs. 11.5% <0.01
Anthracyclines vs. no anthracyclines 43% vs. 23% 21% vs. 5% 0.004
Taxanes vs. anthracycline 28% vs. 43% –  0.03
Biphosphonates vs. no biphosphonates 49% vs. 19% 23% vs. 8% 0.0003
Local treatment in SM
SPT vs. no SPT 48% vs. 24% 21% vs. 11% 0.0003
RT vs. no RT 49% vs. 29% 25% vs. 11% 0.02
Abbreviations – DFI: disease free interval; PS: performance status; HR: hormonal receptors; ER: estrogen receptor; PR: progesterone receptor;
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The median survival for patients who underwent metasta-
sis resection was 83 months.MTS: metastasis; SM: synchronous metastasis; MM: metachronous
chemotherapy; HT: hormonotherapy.
ccording to a sequential schedule in 5 cases (1.9%) and con-
omitant schedule in 8 cases (3%).
After receiving the ﬁrst line CT, the objective response
ate was 65% and the median time for progression was 9
onths.
One hundred and eight patients were treated with HT
immediately to the diagnosis of the metastatic disease in 25
ases, a relay after a response to the ﬁrst line CT in 73 cases
r after the failure of a ﬁrst line CT in 10 cases). Forty-one per-
ent of these patients underwent second-line HT and thirteen
ercent had at least three lines.
Out of 225 patients with bone metastases, only 94 patients
41.7%) received bisphosphonates. Pamidronate was the most
idely used molecule. The average duration of the prescrip-
ion of bisphosphonates was 18.6 months (1–96 months).
.2.3.  Radiotherapy
ne hundred and ﬁfty-ﬁve patients underwent RT, 15 of them
ad only a palliative RT without systemic treatment. It was
rain RT (54 cases), bone RT (78 cases) and/or locoregional RT
23 cases). The response (tumor size reduction) to the LRRT
as observed in 67% of cases. The response to the palliative
T was variable depending on location. Seventy-one percent
f patients with brain metastases showed a disappearance of
ntracranial hypertension symptoms after RT. The relief of the
pinal cord compression was observed in 69% of irradiated
atients. The effectiveness of RT for pain management was
bserved in 90% of cases. The average duration of analgesic
esponse to radiotherapy was 26 weeks.astasis; SPT: surgery of the primitive tumor; RT: radiotherapy; CT:
3.3.  Survival  and  prognostic  factors
In our study, the OS was respectively 63%, 42%, 26% and 12%
at 1, 2, 3 and 5 years (Fig. 1).
The median survival of patients who received treatments
was 18 months. It was 23.3 months, 29.3 months, 18 months,
15 months and 11 months, respectively, in case of only: bone,
lymph node, hepatic, lung or brain MTS.
In patients with single bone MTS, the 5 years OS was 36%
and it was 23% for those with only lymph node metasta-
sis.Fig. 1 – Kaplan–Meier curve for overall survival.
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Table 3 – Prognostic factors in multivariate analysis.
Prognostic factors Hazard ratio (95%) p
General state
PS (0–1) vs. >1 2.59 (1.94–3.46) <0.0001
MTS
Visceral vs. no visceral 1.63 (1.07–2.48) 0.021
Age (years)
<70 vs. >70 1.67 (1.24–2.25) 0.001Abbreviations – PS: performance status; MTS: metastasis.
3.3.1.  Univariate  analysis
Using univariate analysis, the following prognostic factors
were found to inﬂuence positively the survival: Age ≤ 70 years,
good PS (0–1), positive ER, positive PR, single metastatic site,
non visceral MTS,  using HT in ﬁrst line metastatic treatment,
locoregional treatment (RT or/and surgery) in case of SM and
the use of bisphosphonates (Table 2).
3.3.2.  Multivariate  analysis
In case of multivariate analysis, improved survival was asso-
ciated signiﬁcantly with good PS (1–2), non visceral MTS and
age ≤ 70 years (Table 3).
4.  Discussion
In our study, the median survival of SM and MM breast cancer
patients who  received treatment was 18 months and the 5
years OS was 12%. Our results were similar to those reported
in many  previous studies in which the median survival ranged
between 16 and 34 months and the 5 years OS varied from 4%
to 28%.6–10
For many  authors, age at diagnosis is acknowledged as a
prognostic factor affecting the survival. Dawood et al. did not
ﬁnd age to be a prognostic factor for predicting survival.2 How-
ever, according to the study of Largillier et al., poor prognosis
was reported with age over 50 years.11 In our material, we
studied survival according to differing age groups (≤ or >35
years); (≤ or >50 years) and (≤ or >70 years). We identify that
the age of more  than 70 years was a pejorative factor inﬂuenc-
ing signiﬁcantly the survival in univariate and multivariate
analysis.
Some studies have shown that premenopausal women
have a better prognosis than postmenopausal patients.2 This
ﬁnding was not conﬁrmed in our study and the inﬂuence of
the menopausal status on survival was not signiﬁcant.
Several studies have shown that the more  altered the PS is,
the worst the prognosis.12–15 Our study conﬁrmed this ﬁnding
in univariate and multivariate analysis.
Many  previous studies have shown that the DFI is an impor-
tant prognostic factor.2,14,16–21 Vogel et al. reported in a series
of 433 patients with recurrent breast cancer a median sur-
vival from ﬁrst relapse of 26 months for patients with DFI < 24
months and 44 months for patients with DFI > 24 months
(p < 0.01).20 Our study conﬁrmed these ﬁndings; relapse after 2
years of adjuvant therapy was a good prognostic factor.Dawood et al. found that the median survival in women
with SM was 12 months longer than women with MM,
the difference was statistically signiﬁcant in univariate andiotherapy 1 8 ( 2 0 1 3 ) 127–132
multivariate analysis.2 Our study did not conﬁrm these data
and the difference in survival between these two groups was
not statistically signiﬁcant.
The non visceral localizations (skin, soft tissue and bone)
have a better prognosis than visceral sites. The most pejora-
tive visceral sites are the brain, liver and lung.12,21 Our study
conﬁrmed these results as well in univariate or multivariate
analysis.
In our study, the 5 years OS and the median survival with
single bone MTS were respectively 36% and 23.3 months. In
other previous studies, median survival ranged between 24
and 48 months and the 5 years OS achieved 20%.22–24 In a
study conducted by Coleman and Rubens concerning patients
whose cancers were diagnosed in the 1970s and 1980s, the
median survival was 24 months in patients with ﬁrst recur-
rence in the skeleton compared with 3 months after ﬁrst
relapse in the liver (p < 0.01).25
Hepatic metastases are generally associated with a poor
prognosis. Pentheroudakis et al. reported in a retrospective
study of 500 liver metastasis breast cancer cases a median
survival of 16.4 months and 5 years OS of 8.5%.26 Reported
median survivals in a phase III EORTC trial which investigated
the ﬁrst line CT in metastatic breast cancer were respectively
27.1 months and 16.8 months in patients with liver MTS  alone
and with liver with other sites of MTS.4 In our study, median
survival was 17.7 months in cases of hepatic MTS  only. Long
survival (83 months) was obtained in one patient who  under-
went surgical resection of liver MTS.
The median survival for patients with only lung MTS  ranges
from 6 to 15 months as noted in previous studies.24,27 In our
study it was 14.6 months.
The majority of patients with cerebral MTS  died in 40% of
cases because of non control of the latter.28 The median sur-
vival depends on the application of treatment: if not treated,
this median is 1 month; and 2 months for patients who  had
received corticosteroids only, while it grows to 3–6 months if
the whole brain RT is carried out.28 In our study this median
was 11.2 months.
The median survival in case of ovarian and/or peritoneal
metastases, according to previous studies, ranges from 6.4
months to 23 months. However, long term survival reach-
ing more  than 12 years has been reported particularly in
cases of metastatic breast cancer with positive hormonal
receptors.29,30
Many retrospective recent studies have shown that the sur-
gical treatment of the primitive tumor improve the OS rate
for patients presenting breast cancer with SM.31–33 This was
conﬁrmed by our study.
The Le Scodan et al.33 retrospectively reviewed a mono cen-
tric study of 581 treated patients for an SM breast cancer.
Of that number, 320-patients had a loco regional treatment
(exclusive RT for 78% of them, a surgery followed by a RT for
13% and exclusive surgery for 9%), in addition to systemic
treatment against 261 patients who received systemic treat-
ment only. After a median follow-up of 39 months, the 3-year
OS was 43.4% for patients who underwent a local therapy,
against 26.7% for patients who had only systemic treatment
(p < 0.02). Our study showed the beneﬁt provided by a local
therapy (RT and/or surgery) on OS for patients with syn-
chronous metastases of breast cancer.
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The use of biphosphonates in case of bone MTS reduced the
keletal-related events (SREs) rate, delayed the time to SREs
nd prolonged the time in developing bone pain, but it do not
ppear to affect survival.34 However, in our study we noticed
hat the use of biphosphonates improves the overall survival.
.  Conclusion
ur therapeutic results in terms of survival were correlated
ith those of previous studies. Our study conﬁrmed the
ositive impact, inﬂuencing independently the duration of
urvival in metastatic breast cancer, of the good general state,
f the age ≤ 70 years, and of the absence of visceral metastasis.
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